tetano
Editor, Senior Moderator
Virol Sin
. 2020 Aug 31.
doi: 10.1007/s12250-020-00281-8. Online ahead of print.
Patients with Prolonged Positivity of SARS-CoV-2 RNA Benefit from Convalescent Plasma Therapy: A Retrospective Study
Yongran Wu[SUP] 1 [/SUP], Ke Hong[SUP] 2 [/SUP], Lianguo Ruan[SUP] 2 [/SUP], Xiaobo Yang[SUP] 1 [/SUP], Jiancheng Zhang[SUP] 1 [/SUP], Jiqian Xu[SUP] 1 [/SUP], Shangwen Pan[SUP] 1 [/SUP], Lehao Ren[SUP] 1 [/SUP], Lu Chen[SUP] 2 [/SUP], Chaolin Huang[SUP] 3 [/SUP], You Shang[SUP] 4 [/SUP]
Affiliations
Abstract
Convalescent plasma therapy has been implemented in a few cases of severe coronavirus disease 2019. No report about convalescent plasma therapy in treating patients with prolonged positivity of SARS-CoV-2 RNA has been published. In this study, we conducted a retrospective observational study in 27 patients with prolonged positivity of SARS-CoV-2 RNA, the clinical benefit of convalescent plasma therapy were analyzed. qRT-PCR test of SARS-CoV-2 RNA turned negative (≤ 7 days) in a part of patients (early negative group, n = 15) after therapy, others (late negative group, n = 12) turned negative in more than 7 days. Pulmonary imaging improvement was confirmed in 7 patients in early negative group and 8 in late negative group after CP therapy. Viral load decreased in early negative group compared with late negative group at day 3, 5, 7 after implementing convalescent plasma therapy. Patients in early negative group had a shorter median length of hospital stay. In conclusion, convalescent plasma therapy might help eliminate virus and shorten length of hospital stay in patients with prolonged positivity of SARS-CoV-2 RNA.
Keywords: Convalescent plasma therapy; Coronavirus disease 2019 (COVID-19); Prolonged positivity; SARS-CoV-2.
. 2020 Aug 31.
doi: 10.1007/s12250-020-00281-8. Online ahead of print.
Patients with Prolonged Positivity of SARS-CoV-2 RNA Benefit from Convalescent Plasma Therapy: A Retrospective Study
Yongran Wu[SUP] 1 [/SUP], Ke Hong[SUP] 2 [/SUP], Lianguo Ruan[SUP] 2 [/SUP], Xiaobo Yang[SUP] 1 [/SUP], Jiancheng Zhang[SUP] 1 [/SUP], Jiqian Xu[SUP] 1 [/SUP], Shangwen Pan[SUP] 1 [/SUP], Lehao Ren[SUP] 1 [/SUP], Lu Chen[SUP] 2 [/SUP], Chaolin Huang[SUP] 3 [/SUP], You Shang[SUP] 4 [/SUP]
Affiliations
- PMID: 32865701
- DOI: 10.1007/s12250-020-00281-8
Abstract
Convalescent plasma therapy has been implemented in a few cases of severe coronavirus disease 2019. No report about convalescent plasma therapy in treating patients with prolonged positivity of SARS-CoV-2 RNA has been published. In this study, we conducted a retrospective observational study in 27 patients with prolonged positivity of SARS-CoV-2 RNA, the clinical benefit of convalescent plasma therapy were analyzed. qRT-PCR test of SARS-CoV-2 RNA turned negative (≤ 7 days) in a part of patients (early negative group, n = 15) after therapy, others (late negative group, n = 12) turned negative in more than 7 days. Pulmonary imaging improvement was confirmed in 7 patients in early negative group and 8 in late negative group after CP therapy. Viral load decreased in early negative group compared with late negative group at day 3, 5, 7 after implementing convalescent plasma therapy. Patients in early negative group had a shorter median length of hospital stay. In conclusion, convalescent plasma therapy might help eliminate virus and shorten length of hospital stay in patients with prolonged positivity of SARS-CoV-2 RNA.
Keywords: Convalescent plasma therapy; Coronavirus disease 2019 (COVID-19); Prolonged positivity; SARS-CoV-2.